Latest Breaking News On - Mesoblast limited - Page 8 : comparemela.com

Monday, the FDA informed Mesoblast Limited (NASDAQ:MESO) that following additional consideration, the available clinical data from its Phase 3 study MSB-GVHD001 appears sufficient to support submission of the proposed Biologics License Application (BLA) for remestemcel-L for pediatric patients with steroid-refractory acute graft versus host disease (SR-aGVHD). “We thank the agency for their collaborative approach. The responses and guidance from FDA are clear and provide us with a high level of

Silviu itescuInternational bloodWhile the oncologic drugs advisory committeeMesoblast limitedMarrow transplant researchBiologics license applicationOncologic drugs advisory committeeStock market gameBenzinga proDay trialAfter almostMesoblast phaseChildren following stem cell transplantBiologics license applicationPediatric patientsPhase 3 study